Electrochemical proximity assay

Abstract

The present disclosure includes an electrochemical proximity assay (ECPA) which leverages two aptamer or antibody-oligonucleotide probes and proximity-dependent DNA hybridization to move a redox active molecule near an electrically conductive base. The ECPA of the present disclosure produces rapid, quantitative results, enabling point-of-care use in the detection of biomarkers of disease.

Therefore, at least the following is claimed: 
     
         1 . An electrochemical proximity assay (ECPA) comprising:
 forming a nucleic acid layer on an electrically conductive base;   generating an electrical signal by immersing the electrically conductive base comprising the nucleic acid layer into a solution comprising at least one ECPA probe and at least one target, wherein the nucleic acid layer, at least one ECPA probe, and at least one target form a complex; and   quantifying an amount of the target by analyzing the electrical signal, wherein the electrical signal changes in proportion to changes in the concentration of the target.   
     
     
         2 . The ECPA of  claim 1 , wherein the nucleic acid layer comprises at least one surface immobilized nucleic acid strand. 
     
     
         3 . The ECPA of  claim 2 , wherein the surface immobilized nucleic acid strand is selected from the group consisting of: thiolated DNA, amine labeled DNA, RNA, modified RNA, and a combination thereof. 
     
     
         4 . The ECPA of  claim 1 , wherein the nucleic acid layer is formed by covalent attachment of the nucleic acid to the electrically conductive base. 
     
     
         5 . The ECPA of  claim 1 , wherein the electrically conductive base is selected from the group consisting of: a metal electrode, an activated carbon electrode, a conductive ceramic, a conductive glass, and a combination thereof. 
     
     
         6 . The ECPA of  claim 1 , wherein the ECPA probe comprises at least one molecular recognition element specific to the target and at least one nucleic acid/electron transfer conjugate. 
     
     
         7 . The ECPA of  claim 6 , wherein the at least one molecular recognition element is selected from the group consisting of: an aptamer, an antibody, an antibody/DNA conjugate, and a combination thereof. 
     
     
         8 . The ECPA of  claim 1 , wherein the nucleic acid layer further comprises at least one short single stranded nucleic acid competitor. 
     
     
         9 . The ECPA of  claim 8 , wherein the nucleic acid competitor has complimentary bases with at least one nucleic acid strand in the nucleic acid layer. 
     
     
         10 . The ECPA of  claim 9 , wherein the nucleic acid competitor has 5 to 50 complimentary bases with at least one nucleic acid strand in the nucleic acid layer. 
     
     
         11 . The ECPA of  claim 8 , wherein the competitor nucleic acid impedes the hybridization of at least one nucleic acid/electron transfer conjugate. 
     
     
         12 . The ECPA of  claim 1 , wherein the target is selected from the group consisting of: a protein, a small molecule, a multi-protein complex, a nucleic acid, a polymer, a whole cell, a virus, a biological polymer, and a combination thereof. 
     
     
         13 . The ECPA of  claim 11 , wherein the target causes the nucleic acid/electron transfer conjugate to move closer to a surface of the electrically conductive base, replacing the competitor nucleic acid, and allowing an electron transfer process. 
     
     
         14 . The ECPA of  claim 1 , wherein quantification of the target is used in the treatment of health related issues selected from the group consisting of: heart attack, stroke, rhabdomylosis, fertility, diabetes, obesity, metabolic syndrome, sepsis, inflammatory response, food safety, tuberculosis, and a combination thereof. 
     
     
         15 . The ECPA of  claim 1 , wherein multiple targets are quantified simultaneously. 
     
     
         16 . The ECPA of  claim 1 , wherein the complex is re-usable. 
     
     
         17 . The ECPA of  claim 16 , wherein the complex is used for measurement, then washed with a solvent so that the complex is re-useable. 
     
     
         18 . The ECPA of  claim 16 , wherein the complex is washed with a DNA competitor strand, wherein the DNA competitor strand displaces the previously immobilized ECPA probe. 
     
     
         19 . A method for quantifying a target in a sample comprising:
 mixing a nucleic acid with a competitor DNA;   immobilizing the nucleic acid/competitor DNA on an electrically conductive base to form a nucleic acid/competitor DNA layer;   mixing the target with at least one molecular recognition element and at least one nucleic acid/electron transfer conjugate to form a probe/target solution;   immersing the electrically conductive base comprising the nucleic acid/competitor DNA layer into the probe/target solution to generate an electrical signal; and   quantifying the target by analyzing the electrical signal, wherein the electrical signal increases in proportion to the concentration of the target.   
     
     
         20 . The method of  claim 19 , wherein the target is identified by analyzing the electrical signal. 
     
     
         21 . The method of  claim 19 , wherein the at least one molecular recognition element is selected from the group consisting of: an aptamer, an antibody, an antibody/DNA conjugate, and a combination thereof. 
     
     
         22 . The method of  claim 19 , wherein the competitor DNA comprises complimentary bases with the nucleic acid. 
     
     
         23 . The method of  claim 19 , wherein the sample comprises a biological sample selected from the group consisting of: blood serum, whole blood, nasal aspirates, saliva, urine, feces, cell lysate, dialysis sampling, tissue biopsy, cell media, and a combination thereof. 
     
     
         24 . The method of  claim 23 , wherein the biological sample is unprocessed. 
     
     
         25 . The method of  claim 19 , wherein the target is selected from the group consisting of: a peptide, a protein, a small molecule, a whole cell, a multi-protein complex, a nucleic acid, a virus, and a combination thereof. 
     
     
         26 . The method of  claim 19 , wherein the method is used at the point-of-care (POC) to detect biomarkers of disease. 
     
     
         27 . The method of  claim 19 , wherein a concentration of target in the sample as low as about 1 attomolar (10 −18  mol/dm 3 ) is detected. 
     
     
         28 . The method of  claim 19 , wherein the target is quantified using a readout method selected from the group consisting of: surface plasmon resonance (SPR), Raman spectroscopy, and a combination thereof. 
     
     
         29 . A complex comprising:
 a surface immobilized nucleic acid;   a first molecular recognition element;   a target;   a second molecular recognition element; and   a nucleic acid/electron transfer conjugate.   
     
     
         30 . The complex of  claim 29 , wherein the surface immobilized nucleic acid is covalently attached to an electrically conductive base, the first and second molecular recognition elements are specific to and bound to the target, and the complex comprises a circular structure on the electrically conductive base through proximity dependent hybridization of the surface immobilized nucleic acid and the nucleic acid/electron transfer conjugate. 
     
     
         31 . The complex of  claim 29 , wherein the surface immobilized nucleic acid is selected from the group consisting of: a thiolated DNA, an amine labeled DNA, an RNA, a modified RNA, and a combination thereof. 
     
     
         32 . The complex of  claim 29 , wherein the nucleic acid/electron transfer conjugate comprises a methylene blue conjugated DNA (MB-DNA). 
     
     
         33 . The complex of  claim 29 , wherein the first and second molecular recognition elements are each independently selected from the group consisting of: an aptamer, an antibody, an antibody/DNA conjugate, and a combination thereof. 
     
     
         34 . The complex of  claim 29 , wherein the target is selected from the group consisting of: a peptide, a protein, a small molecule, a whole cell, a multi-protein complex, a nucleic acid, a virus, and a combination thereof. 
     
     
         35 . The complex of  claim 29 , further comprising at least one short single stranded nucleic acid competitor to the surface immobilized nucleic acid, wherein the nucleic acid competitor has complimentary bases with the surface immobilized nucleic acid.